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368a Monday, February 17, 2014topologically equivalent 5-helix repeats. Importantly, we show that these
changes result in the opening and closing of water-filled pathways that reach
from either side of the membrane into the proton binding site, which is found
at the interface between repeats, half-way through the membrane. More specif-
ically, the transition between the L T, and O states of the functional cycle rep-
resents a change from inward to outward to inward-facing conformations.
Interestingly, our analysis also shows that the structural changes associated
with this alternating-access mechanism differ in the proton-free (L to T) and
proton-loaded (T to O) portions of the cycle, a feature that might be shared
by other ion-coupled secondary transporters. Finally, we propose a mechanism
of strict coupling between transmembrane and periplasmic domains, and thus
between proton-import and drug-efflux.
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Insertion and release of a solute into and from a vessel comprising biopoly-
mers is a fundamental function. A typical example is found in a multidrug
efflux transporter. ‘‘Multidrug efflux’’ signifies that solutes such as drug mol-
ecules with diverse properties can be handled. In earlier works, we showed
that the spatial distribution of the solute-vessel potential of mean force
(PMF) induced by the solvent plays imperative roles in the insertion/release
process. The PMF can be decomposed into the energetic and entropic com-
ponents. The entropic component, which originates from the translational
displacement of solvent molecules, is rather insensitive to the solute-
solvent and vessel inner surface-solvent affinities. This feature is not shared
with the energetic component. When the vessel inner surface is neither
solvophobic nor solvophilic, the solvents within the vessel cavity and in
the bulk offer almost the same environment to any solute, and the energetic
component becomes much smaller than the entropic component. Our idea is
that the multidrug efflux can be realized if the insertion/release process is
accomplished by the entropic component. However, we have recently argued
that the entropic release is not feasible as long as the vessel geometry is
fixed. Here we consider a model of TolC, a cylindrical vessel possessing
an entrance at one end and an exit at the other end for the solute. The spatial
distribution of the PMF is calculated by employing the three-dimensional in-
tegral equation theory with rigid-body models whose behavior is purely
entropic in origin. We show that the entropically inserted solute can be
released by a continuous variation of the vessel geometry which forms a
time-dependent entropic force continuing to accelerate the solute motion to
the exit. Solutes with a wide range of sizes are entropically released using
the same vessel-geometry variation.
1856-Pos Board B586
Structure and Function of a Phosphorylation-Coupled Saccharide
Transporter
Jason G. McCoy1, Sharmistha Mitra1, Elena J. Levin1, Hua Huang1,
Jumin Lee2, Wonpil Im3, Matthias Quick4,5, Brian Kloss6, Renato Bruni6,
Ming Zhou1.
1Department of Biochemistry and Molecular Biology, Baylor College of
Medicine, Houston, TX, USA, 2Center for Bioinformatics, University of
Kansas, Kansas City, KS, USA, 3Department of Molecular Biosciences and
Center for Bioinformatics, University of Kansas, Kansas City, KS, USA,
4Department of Psychiatry and Molecular Recognition, Columbia University,
New York, NY, USA, 5Division of Molecular Therapeutics, New York State
Psychiatric Institute, New York, NY, USA, 6New York Consortium on
Membrane Protein Structure, New York, NY, USA.
The bacterial phosphotransferase system (PTS) drives unidirectional transport
of saccharides across the inner cell membrane and signals the intracellular
availability of these sugars. Directionality of transport is accomplished through
phosphorylation of the sugar by the soluble protein enzyme IIB (EIIB) while it
is bound to the component of the PTS responsible for translocation, the integral
membrane protein enzyme IIC (EIIC). The first crystal structure of an EIIC was
recently reported1. The N,N’-diaceylchitobiose transporter, a homolog of
E. coli ChbC, was crystallized in a state in which the bound substrate is not sol-
vent accessible from either side of the membrane. In order to further charac-
terize the EIIC conformational changes needed to translocate the sugar
molecule across the bilayer and covalently modify the sugar, we have taken
several approaches. We cloned and screened 91 ChbC homologs with the
goal of solving structures that assume different solvent accessbility to the
bound substrate. We found 11 homologs that are suitable for crystallization,7 of which contain an EIIB domain. Molecular dynamics simulations, as
well as mutational studies, were conducted to investigate motions of domains
that are responsible for substrate translocation and phosphorylation.
1 Cao, Y.; et al., Crystal Structure of a phosphorylation-coupled saccharide
transporter. Nature2011, 473 (7345), 50-54.
1857-Pos Board B587
Functional Coupling of a Urate-Anion Exchanger URAT1 and Sodium-
Dependent Anion Transporter SMCT2 on a PDZK1 Scaffold; Proposal
of ‘‘Transportsome’’ for Urate-Transport
Shushi Nagamori, Pattama Wiriyasermkul, Yasuhiro Umemura,
Noriyoshi Isozumi, Yumiko Nishinaka, Yoshikatsu Kanai.
Osaka University Graduate School of Medicine, Suita Osaka, Japan.
Transporters utilize electrochemical gradients across membranes to translo-
cate their substrates through the membranes. Many eukaryotic plasma mem-
brane symporters transport substrates in a Naþ-dependent manner by using
an electrochemical Naþ gradient across plasma membranes, while exchangers
couple the movement of a substrate against its electrochemical gradient with
the movement of another substrate down its electrochemical gradient in the
opposite direction. Although the Naþ gradient is ubiquitous and stable, the
electrochemical gradients of substrates for exchangers usually depend on cells
and are affected by cellular conditions. The concentrations of intracellular
substrates limit the accumulation of extracellular substrates thorough ex-
changers. To overcome the constraint, exchangers need to couple with other
proteins that help accumulation of substrates around exchangers. We have
been proposing that such functional coupling of transporters is general and
constitutes the functional unit of transport that we call ‘‘transportsome’’.
Here, we show one of the examples. Proteomics analysis following
co-immunoprecipitation revealed that urate-anion exchanger URAT1 and
Naþ-dependent anion transporter SMCT2 formed a complex through scaffold
protein PDZK1 in the apical membrane of renal proximal tubules. FRET
experiment clearly indicated that PDZK1 assembled URAT1 and SMCT2 in
living cells. To elucidate functional coupling of the transporters, URAT1
and SMCT2 were overexpressed in insect cells, purified and reconstituted
into proteoliposomes in the presence or absence of PDZK1. The initial rate
of urate-uptake was increased in the presence of Naþ when co-reconstituted
with PDZK1 while Naþ did not alter the rate without PDZK1. These results
suggest that SMCT2 generate an electrochemical gradient of the substrate
which drives the urate-uptake via URAT1 located in close proximity to
SMCT2 with PDZK1 scaffold. Taken together, the transporters and the scaf-
fold protein formed Transportsome for urate-transport.
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Folate cofactors, Vitamin B9, play crucial roles in more than a hundred one-
carbon metabolism reactions in mammalian cells. Humans cannot synthesize
folates de novo and absorption through the diet is the only source of this
vitamin. The proton-coupled folate transporter (PCFT) mediates this uptake
in the upper small intestine by a pH-dependent process. PCFT also transports
folates into the central nervous system. Point mutations in the PCFT gene
cause Hereditary Folate Malabsorption (HFM), with associated hematological
and neurological defects due to impaired folate transport. Certain solid tumor
cell lines express high levels of PCFT mRNA. Importantly, the overall expres-
sion of PCFT is limited to only certain tissues in humans. Therefore, PCFT is
a molecular target for specific delivery of anti-folate chemotherapeutic agents
to tumor cells. Unfortunately, the success rate of anti-folate agents to reach
clinical use is very low due to their side-effects. A structural model of
PCFT can aid the development of specific anti-folate agents for their
PCFT-targeted delivery and thus minimize their side-effects. To optimize
and verify an initial structural model of PCFT, we applied a wide array of
experimental approaches: solvent accessibility profiling through substituted
cysteine accessibility scanning, studying the helix packing, and assaying the
functionality of PCFT mutants. We complemented the experimental data
with theoretical approaches for structure prediction such as homology
modeling/threading, ligand docking and an extensive review of other second-
ary transporters and folate transport proteins. With these combined ap-
proaches, we have developed a structural model of PCFT that accurately
reflects our experimental observations. This model forms a basis to understand
the impacts of HFM mutations, and to develop folate analogues for folate defi-
ciency intervention. Additionally, it will aid the design of PCFT structure-
based anti-folate agents for the treatment of cancer.
